Back to search results
NCT06654466

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Active, Not Recruiting
NAAges 18–49InterventionalSupportive care
Nest Genomics
~100 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acceptability of Intervention Measure (AIM)
Measured over within 7 days of visit
+4 more outcomes measured

Conditions

Hereditary Cancer Syndromes
Clinical Decision Support

Explore related trials

Hereditary Neoplastic SyndromeHereditary Neoplastic Syndrome

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Huma Q Rana, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
  • Jennifer W Mack, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 18-49 years, inclusive
previous cancer genetic testing with a finding of a pathogenic or likely pathogenic variant resulting in an increased risk of cancer warranting clinical management.
English-speaking and -reading
Receiving care at Dana Farber Cancer Institute
Not in active cancer therapy at the time of approach

Exclusion

Age \<18 or \>49 years
Has not had genetic testing for hereditary cancer syndromes or has been tested but no pathogenic or likely pathogenic variant was identified.
Non-English speaking and reading
Not receiving care at Dana Farber Cancer Institute
Active cancer with therapy in progress

What this trial measures

  • Acceptability of Intervention Measure (AIM)within 7 days of visit

    A 4-item measure of intervention acceptability on a 5-point Likert response scale designed for a range of stakeholders. Demonstrated to be associated with intervention success.

  • Gist Comprehension of Genetic Cancer RiskBaseline, within 7 days of visit

    Modified items from the Gist Comprehension of Genetic Cancer Risk (alpha=.85) ask patients their likelihood of future cancer on a 5-point Likert scale, higher score indicating greater comprehension.

  • Knowledge of Cancer ScreeningBaseline, within 7 days of visit

    An 11-item true-false scale (Cronbach's alpha=.81) will measure knowledge of cancer screening recommendations. Higher score indicates greater knowledge, minimum score=0, maximum score=11. Items will be modified for cancer risk syndromes under study.

  • Psychosocial Aspects of Hereditary Cancer (PAHC)Baseline, within 7 days of visit

    A 26-item questionnaire organized into six problem domains: genetics, practical issues, family, living with cancer, emotions, and children. Higher score indicates greater emotional distress. Validated in adults with hereditary cancer risk.

  • Distress Thermometer (DT)Baseline, within 7 days of visit

    A visual-analog scale from 0-"no distress" to 10-"extreme distress" to assess general psychological distress. Higher score indicates greater distress. Pairing with the PAHC enhances sensitivity and specificity.